Tactile Systems Technology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
37.9%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$364.8Mnext fiscal year
FY EPS (est.)
$1.10next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 2 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Growth (YoY) Quarterly2,300.0%Target: 9% to 12% for FY 2026
Gross Margin Quarterly7,650.0%Target: Sustained expansion above 75%
Adjusted EBITDA Quarterly3.7MTarget: $49 million to $51 million for FY 2026
Watch Items
- Medicare Prior Authorization RequirementsTrigger: Implementation of prior authorization for Pneumatic Compression Devices (PCDs)Action: Monitor operational agility and utilization of the AI-enabled order management platform to prevent order processing delays.
- LymphaTech Integration and CommercializationTrigger: Post-acquisition product rollout and clinical adoptionAction: Track sales rep productivity and diagnostic tool adoption rates among direct-to-provider channels.
- Competitive Wearable Devices (e.g., Koya Dayspring)Trigger: Clinical trial readouts confirming superior limb volume reductionAction: Assess market share defense via the newly launched Nimbl pneumatic compression platform.
Research as of 19 Jun 2026